Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 100204
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.100204
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.100204
Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis
Ren-Hao Hu, Dong-Yi Yan, Ke-Hui Zhang, Di Zhang, Xi-Mao Cui, Xiao-Hua Jiang, Shun Zhang, Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China
Dong-Yi Yan, Ke-Hui Zhang, School of Medicine, Tongji University, Shanghai 200092, China
Di Zhang, Department of Emergency Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China
Co-first authors: Ren-Hao Hu and Dong-Yi Yan.
Co-corresponding authors: Xiao-Hua Jiang and Shun Zhang.
Author contributions: Hu RH, Yan DY, Zhang KH, Cui XM, and Zhang S performed material preparation, data collection, and analysis; Zhang S and Jiang XH wrote the first draft of the manuscript; Yan DY aided in the manuscript writing and finalized the manuscript; Zhang S and Jiang XH discussed the content and critically reviewed the manuscript draft; All authors contributed to the study conception and design, and read and approved the final manuscript. Hu RH and Yan DY contributed equally to this work as co-first authors. Jiang XH and Zhang S were appointed for this paper. First, the two professors participated in the design of the research study, provided research ideas, and made important revisions to the paper during the writing process, and finally finalized the manuscript. Second, these two professors played a significant role in project management and team collaboration. Therefore, both corresponding authors have made important and equal contributions to the article. For this reason, the article designates these two as co-corresponding authors.
Supported by Pudong New Area Science and Technology Development Fund for Livelihood Research Special Project, No. PKJ2023-Y38.
Institutional review board statement: The study was approved by the Human Research Ethics Committee of Shanghai East Hospital.
Informed consent statement: All participants signed the informed consent.
Conflict-of-interest statement: The authors have no conflicts of interests to declare.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shun Zhang, MD, PhD, Assistant Professor, Department of Gastrointestinal Surgery, Shanghai East Hospital, School of Medicine, Tongji University, No. 1800 Yuntai Road, Pudong New District, Shanghai 200120, China. v2zs@hotmail.com
Received: August 9, 2024
Revised: October 16, 2024
Accepted: October 29, 2024
Published online: January 15, 2025
Processing time: 124 Days and 18.9 Hours
Revised: October 16, 2024
Accepted: October 29, 2024
Published online: January 15, 2025
Processing time: 124 Days and 18.9 Hours
Core Tip
Core Tip: Timely identification of colorectal cancer (CRC) is essential in lowering both the occurrence and death rates linked to the illness. It has been shown that serum lipids and insulin resistance (IR) markers can be useful biomarkers for detecting CRC in patients. This article retrospectively analyzed 277 patients with CRC and investigated the clinical diagnostic value of a combination of IR indicators, including the triglyceride-glucose index and atherosclerotic index, with cancer antigens as a novel diagnostic marker for CRC.